Free Trial
NASDAQ:TAOX

Synaptogenix Q4 2025 Earnings Results & Report

Synaptogenix logo
$3.50 -0.18 (-4.76%)
As of 02:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Synaptogenix reported Q4 2025 earnings on March 31, 2026. The company reported EPS of $1.03, while revenue was ($2.46) million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Synaptogenix EPS Results

Actual EPS
$1.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
($2.46) million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Synaptogenix Q4 2025 Earnings FAQ

Synaptogenix (NASDAQ:TAOX) reported earnings of $1.03 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026.

Synaptogenix reported revenue of ($2.46) million for Q4 2025.

Synaptogenix Earnings Headlines

Synaptogenix (NASDAQ:TAOX) & Otsuka (OTCMKTS:OTSKY) Critical Contrast
Comparing Innoviva (NASDAQ:INVA) and Synaptogenix (NASDAQ:TAOX)
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.tc pixel
Synaptogenix (NASDAQ:TAOX) Cut to Sell at Wall Street Zen
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:TAOX) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and disorders involving memory and cognitive function. The company has primarily investigated treatments designed to support synaptic function and neuronal health.

Its lead research program has centered on bryostatin-1, a naturally derived compound being studied for its potential to activate protein kinase C epsilon and improve cognitive function in patients with Alzheimer’s disease. Synaptogenix has also explored potential applications of its technology in other neurological conditions, although its programs remain investigational and the company does not have an established portfolio of approved commercial products.

The company was formerly known as Neurotrope, Inc. and adopted the Synaptogenix name as it refined its focus on neurodegenerative disease research. Public information identifies Synaptogenix with the Nasdaq ticker SNPX; the ticker symbol TAOX appears to refer to a different issuer. Accordingly, the company and symbol provided should be independently verified before use.

View Synaptogenix Profile